We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Opthea Limited is a biotechnology business based in Australia. Opthea shares (OPT) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Opthea has a trailing 12-month revenue of around $95,563. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $1.09 - $2.25 |
|---|---|
| 50-day moving average | $1.2565 |
| 200-day moving average | $1.373 |
| Target price | $2.44 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.199 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$1.105
| 1 week (2021-11-29) | -9.05% |
|---|---|
| 1 month (2021-11-05) | -11.60% |
| 3 months (2021-09-06) | -20.22% |
| 6 months (2021-06-04) | -25.34% |
| 1 year (2020-12-04) | -50.67% |
|---|---|
| 2 years (2019-12-06) | -62.54% |
| 3 years (2018-12-06) | 97.32% |
| 5 years (2016-12-06) | 63.70% |
| Revenue TTM | $95,563 |
|---|---|
| Gross profit TTM | $-333,338 |
| Return on assets TTM | -26.38% |
| Return on equity TTM | -50.42% |
| Profit margin | 0% |
| Book value | 0.385 |
| Market capitalisation | $419.4 million |
TTM: trailing 12 months
We're not expecting Opthea to pay a dividend over the next 12 months.
Opthea 's shares were split on 14 August 1997.
Over the last 12 months, Opthea 's shares have ranged in value from as little as $1.09 up to $2.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Opthea 's is -0.1814. This would suggest that Opthea 's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Opthea has bucked the trend.
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
The emergency room is no place for the faint of heart.
We run through how you buy and trade cryptocurrencies on the Binance exchange.
The past 7 days have seen ETH iron out its recent volatility-induced losses.
The last 30-days have seen BTC register substantial losses of over 10%.
Australia's best weekend deals include 50% off at BCF, half-price ASICS shoes at Foot Locker, 80% off hot fashion at Nasty Gal.
Today's best online deals include: $130 off Philips air fryers, $250 off Apple AirPods Max, 50% off at Myer.
Here are the Christmas delivery cut-off dates for 50 major Australian retailers.
Kayo Sports, Australia's leading sports streaming platform, is offering a ridiculous deal for a short time.
Steps to owning and managing Alphabet shares from in Australia.
